Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Monarch Capital Management Inc.

Monarch Capital Management Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 564 shares of the biopharmaceutical company’s stock after selling 20 shares during the period. Monarch Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $593,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $932,571,000. Global Assets Advisory LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth approximately $339,594,000. Capital International Investors lifted its position in Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after buying an additional 213,038 shares in the last quarter. First Trust Advisors LP raised its holdings in shares of Regeneron Pharmaceuticals by 115.2% during the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock valued at $321,410,000 after purchasing an additional 195,902 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after purchasing an additional 184,561 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

REGN has been the topic of several research analyst reports. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Canaccord Genuity Group restated a “buy” rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Evercore ISI initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target on the stock. Argus boosted their price target on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. Finally, Piper Sandler boosted their price target on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research report on Friday. One analyst has rated the stock with a sell rating, three have given a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $1,108.45.

Insider Buying and Selling

In related news, Director Michael S. Brown sold 1,172 shares of the stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at $1,347,256.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $1,011.00, for a total value of $836,097.00. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,397,202. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael S. Brown sold 1,172 shares of the stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at $1,347,256.52. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,731 shares of company stock worth $18,230,142. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Up 1.0 %

Shares of Regeneron Pharmaceuticals stock traded up $11.46 on Friday, hitting $1,199.12. The company had a trading volume of 352,601 shares, compared to its average volume of 470,701. The firm has a market capitalization of $132.13 billion, a P/E ratio of 35.42, a P/E/G ratio of 3.12 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a twelve month low of $769.19 and a twelve month high of $1,203.49. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The stock has a 50-day moving average of $1,088.06 and a 200-day moving average of $1,004.04.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $8.79 earnings per share. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.